title: Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis.
abstract: BACKGROUND
  Hepatocellular carcinoma is one of the leading causes of death for compensated chronic liver disease.
  
  
  OBJECTIVE
  The evaluation of technical success as primary ablation rate, local tumor progression, safety, and long--term patients outcome of radiofrequency ablation in single (less than 3.5 cm in diameter) or multiple nodules (up to 3, sized less than 3 cm) of hepatocellular carcinoma associated to chronic liver disease without cirrhosis.
  
  
  METHODS
  25 consecutive patients, mainly chronic hepatitis C, with surgical unresectable hepatocellular carcinoma due to comorbidity or tumor location recruited from a local sonographic screening, were treated.
  
  
  RESULTS
  Primary ablation was obtained in 96% of patients (24 out of 25) and in 93 % of nodules (27 out of 29). 1, 3, and 5-year local tumor progression rates after treatment were 4, 14, and 14%. Survival rates at 1,3, and 5-year were 92, 72, and 64%. No treatment-related deaths and severe complications were recorded.Conclusions. Radiofrequency ablation is effective with 96% of primary ablation with few tumoral recurrence and limited morbidity in patients with hepatocellular carcinoma associated with chronic liver disease without cirrhosis, it could represent a valid alternative treatment whenever surgical therapy is not safe.
authors.affiliation: Gastroenterology Unit AFAR, Ospedale S.Orsola Fatebenefratelli Brescia Italy. asalmi@fatebenefratelli.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Salmi
authors.forename: Renato
authors.initials: R
authors.lastname: Turrini
authors.forename: Giovanna
authors.initials: G
authors.lastname: Lanzani
authors.forename: Antonella
authors.initials: A
authors.lastname: Savio
authors.forename: Livio
authors.initials: L
authors.lastname: Anglani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000150:complications* / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis; D008113:Liver Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D015996:Survival Rate